Brixton Biosciences Nabs $33M to Advance Novel Pain Therapies
Sameer Sabir, Chief Executive Officer of Brixton Biosciences
What You Should Know:
– Brixton Biosciences, a clinical-stage life sciences company focused on innovative pain treatments raises $33M in Series B funding led by Schooner Capital with…
Continue Reading